In summary, the overexpression of SMAD6 led to the downregulation of the TGF-β signaling pathway in bladder cancer, thereby inhibiting cancer cell EMT and reducing the progression and metastasis of bladder cancer. Here, SMAD6 is linked to urinary bladder cancer.